Cisco study: Data privacy issues can delay sales | Latest News
Adaptative Biotechnology announced today that it has partnered with Microsoft to plan the genetics of the human immune system, with the objective of detecting cancers and other diseases in its early stages. The association will combine Adaptive immune sequencing technology with Microsoft search and large-scale machine learning and cloud computing capabilities. Collaborators intend to develop diagnostics of individual illness at the beginning, and finally develop a diagnosis of universal illness from a single blood test. According to the terms of the agreement, Microsoft also made a financial investment not specified in Adaptive. "This announcement comes at a turning point in the field of healthcare and biotechnology. Now we have the technology to do what we have been talking about during the last decade: we develop a map of universal antigen [receptor of T cells] that presents an opportunity to help patients on an unprecedented scale, "the customizable president,